Novartis (NVS) Stock Surges 5% Following Positive Multiple Sclerosis Drug Trial Results
Key Takeaways Shares of Novartis climbed approximately 5% following positive Phase 3 trial outcomes for remibrutinib, an oral multiple sclerosis treatment The experimental drug outperformed t







